Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome

NCT06694363 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT06694363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06694363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Recruiting
Start date
June 26, 2025
Completion date
December 27, 2029
Enrollment
14 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

activated pi3k delta syndrome